Vol 18, No 1  2020

ISSN 1933-0863 (PRINT)    ISSN 1933-0871 (ONLINE)

Home               Archives               About Us             Submission Guidelines              Editorial Board              Advertising Information               Contact Us

Consensus Statement Sets New Benchmark for Immunotherapy Guidelines in RCC

 

As a new standard in the field, every patient should receive an anti-PD-1-based therapy as initial treatment unless there is a specific contraindication to this approach. However, there remains a need for biomarkers to better predict patient response and to help decide the best treatment approach for each patient. Additionally, it remains to be determined whether new IO combinations including VEGFR TKIs will elicit properties of IO therapy, enabling the patient the ability to stop treatment with persistent benefit.”

     These are among the conclusions of a comprehensive and thoroughly researched consensus statement with special relevance to those of us engaged in kidney cancer care. The document is The Society for Immunotherapy of Cancer Consensus Statement on Immunotherapy for the Treatment of Advanced Renal Cell Carcinoma (RCC).

     Let’s start with the credentials of the group spearheading this initiative. It was my privilege to serve among the 19 members of the Society for Immunotherapy of Cancer (SITC) panel, a group with literally hundreds of years of clinical practice and clinical trial experience. This subcommittee included expert physicians, nurses, scientists, and a patient advocate who regularly communicated via email, teleconference, and in-person between September 2018 and June 2019 to review existing new data and determine how to incorporate these results into updated RCC-specific consensus management guidelines.  (continue) 

 

Robert A. Figlin, MD

Implications of VHL-HIF Pathway Dysregulation in Renal Cell Carcinoma: Current Therapeutic Strategies and Challenges

 

Eric Jonasch, MD

Professor, Department of Genitourinary Medical Oncology

Director, The Von Hippel Lindau Clinical Center

The University of Texas MD Anderson Cancer Center

Houston, TX      Read

ROUNDTABLE

Reinventing the Paradigm of IL-2 Therapy: Pivotal Trial Could Change the Landscape of Combination Strategies in Advanced RCC

 

Robert A. Figlin, MD1, Nizar Tannir, MD2,
Arif Hussain, MD
3

 

1Editor-in-Chief of Kidney Cancer Journal

2Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas

3Professor of Medicine, University of Maryland Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine
Baltimore, Maryland    Read

Back to Interleukin 2 After Four Decades:
Review of the History, Biology, Novel Approaches and Clinical Trials

 

Elshad Hasonov, MD, PhD1,  Adi Diab, MD2,
Nizar M. Tannir, MD, FACP1

 

1Department of Genitourinary Medical Oncology,
Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX

2Department of Melanoma Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center,
Houston, TX     Read

 

 

To view the current issue

as a PDF file, click here

Essential Peer-Reviewed
Reading in Kidney Cancer

 

The peer-reviewed articles summarized in this section were selected by the Editor-in-Chief, Robert A. Figlin, MD, for their timeliness, importance, relevance,and potential impact on clinical practice or translational research.

 

Imaging of tumour response to immunotherapy. Dromain C,Beigelman C, Pozzessere C, et al.  Eur Radiol Exp. 2020 Jan 3;4(1):2. doi: 10.1186/s41747-019- 0134-1.

Summary: The novel mechanism of action of immune checkpoint inhibitors (CPIs), with immune and T cell activation, leads to unusual patterns of response on imaging, with the advent of so-called pseudoprogression being more pronounced and frequently observed when compared to other anticancer therapies. Pseudoprogression, described in about 2-10% of patients treated with ICIs, corresponds to an increase of tumour burden and/or the appearance of new lesions due to infiltration by activated T cells before the disease responds to therapy. To overcome the limitation of response evaluation criteria in solid tumors (RECIST) to assess these specific changes, new imaging criteria-so-called immune-related response criteria and then immune-related RECIST (irRECIST)-were proposed. The major modification involved the inclusion of the measurements of new target lesions into disease assessments and the need for a 4-week re-assessment to confirm or not confirm progression. The RECIST working group introduced the new concept of “unconfirmed progression”, into the irRECIST.

Conclusion: This paper reviews current immunotherapeutic approaches and summarizes radiologic criteria to evaluate new patterns of response to immunotherapy. Furthermore, imaging features of immunotherapy-related adverse events and available predictive biomarkers of response are presented.    (continue)

Is Circulating Tumor DNA Ready for Prime Time? Evaluation of this Biomarker in the Era of Precision Medicine

 

Ritesh R. Kotecha, MD

Medical Oncology Fellow

Department of Medicine

Memorial Sloan Kettering Cancer Center

New York, New York      Read

 

 

Newsworthy, late-breaking information from Web-based sources, professional societies, and government agencies

 

Highlights from the IKCS, Miami, November 14-16: New Data on Combination Therapy, Potential Strategy in Refractory RCC, and Brain Mets

More than 400 attendees gathered in Miami for the 18th International Kidney Cancer Symposium, as key opinion leaders presented emerging and pivotal data from an agenda representing the most comprehensive information available on kidney cancer. Selected highlights are covered here. Detailed results and perspectives on the scientific symposium are available on the Kidney Cancer Association website.

 

To view slides of all presenters, please visit: http://www.euikcs.com/kca/miami2019

To view videos of all presentations, please visit:
https://www.oncologytube.com/channel/kidneycancer

                                                     (continue)

The Official Journal of the Kidney Cancer Association

Home      Archives      About Us      Submission Guidelines         Editorial Board       Advertising Information      Contact Us

This paper reviews current immunotherapeutic approaches and summarizes radiologic criteria to evaluate new patterns of response to immunotherapy. Furthermore, imaging features of immunotherapy-related adverse events and available predictive biomarkers of response are presented.   

Elshad Hasonov, MD, PhD1,  Adi Diab, MD2,
Nizar M. Tannir, MD, FACP1